BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36562382)

  • 1. Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
    Lombardi P; Aimar G; Peraldo-Neia C; Bonzano A; Depetris I; Fenocchio E; Filippi R; Quarà V; Milanesio M; Cavalloni G; Gammaitoni L; Basiricò M; Cagnazzo C; Ostano P; Chiorino G; Aglietta M; Leone F
    Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity.
    Wang Y; Wang W; Dong H; Wang G; Chen W; Chen J; Chen W
    Front Oncol; 2023; 13():1017237. PubMed ID: 36937428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
    Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
    Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
    Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
    Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing chronic kidney disease and hypertension increased the risk of cardiotoxicity among colorectal cancer patients treated with anticancer drugs.
    Ho CC; Wen PC; Yu WC; Hu YW; Yang CC
    J Chin Med Assoc; 2021 Sep; 84(9):877-884. PubMed ID: 34320515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Saneeymehri SS; Markey KR; Mahipal A
    J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of major adverse cardiac event in low risk chest pain patients in emergency department of Rajavithi Hospital.
    Piyanuttapull S; Ledarmonpat T
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S111-6. PubMed ID: 25509704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vectorcardiography risk stratifies emergency department chest pain patients with left ventricular hypertrophy on the initial 12-lead ECG.
    Fesmire FM; Eriksson SV
    Ann Noninvasive Electrocardiol; 2004 Apr; 9(2):149-55. PubMed ID: 15084212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity.
    Cucciniello L; Bidoli E; Viel E; Canale ML; Gerratana L; Lestuzzi C
    Front Cardiovasc Med; 2022; 9():960240. PubMed ID: 36186986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
    Li C; Chen L; Chou C; Ngorsuraches S; Qian J
    Cardiovasc Toxicol; 2022 Feb; 22(2):130-140. PubMed ID: 34792740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
    Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
    J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
    Moghaddam Z; Rostami M; Zeraatchi A; Abadi H; Karamitanha F; Amirmoghaddami H
    Exp Oncol; 2022 May; 44(1):60-66. PubMed ID: 35548958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term symptom burden and quality of life in patients hospitalised with chest pain: a prospective observational study.
    Saeed N; Norekvål TM; Steiro OT; Tjora HL; Langørgen J; Bjørneklett RO; Skadberg Ø; Bonarjee VVS; Mjelva ØR; Omland T; Vikenes K; Aakre KM
    BMJ Open; 2022 Jul; 12(7):e062302. PubMed ID: 35831040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the incidence of major adverse cardiac events in emergency department chest pain patients with a normal ECG, thrombolysis in myocardial infarction score of zero and initial troponin <=99th centile: an observational study?
    Kelly AM
    Emerg Med J; 2013 Jan; 30(1):15-8. PubMed ID: 22328637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.
    De Iuliis F; Salerno G; Taglieri L; De Biase L; Lanza R; Cardelli P; Scarpa S
    Tumour Biol; 2016 Mar; 37(3):3379-87. PubMed ID: 26449821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.